The Heads of HTA Agencies Group (HAG) has adopted its Strategic Plan 2025–2028, a comprehensive roadmap designed to strengthen the health technology assessment (HTA) collaboration and landscape across Europe. Developed through extensive consultation and collective reflection among the members of the HAG, the document sets an agenda to promote a Europe in which HTA contributes to timely, fair, and sustainable patient access to health technologies with added benefit.
The Strategic Plan outlines this shared vision for a European HTA ecosystem, built in line with the mission of the HAG to support strong strategic partnerships and to promote effective and efficient solutions for a European HTA collaboration. To achieve this, the plan is structured around six key strategic areas:
- Enhance HTA capability, capacity and knowledge across the EU/EEA HTA bodies
- Create strategic alliances with relevant stakeholders
- Strengthen voluntary and strategic cooperation
- Promote the value of HTA in European healthcare systems
- Strengthen HAG communication
- Ensure sustainability of the collaboration
The adoption of the new strategy marks a milestone for European HTA collaboration, coinciding with the ongoing rollout of the HTAR. On behalf of HAG, Rui Santos Ivo, Chair of the HAG highlighted the strategic significance of this joint plan: “[The Strategic Plan 2025–2028] reflects the collective commitment of HTA bodies across Europe to work together in shaping an efficient, responsive, and sustainable HTA ecosystem” stating that it “sets a common direction to address these challenges and to seize opportunities for greater collaboration and impact, particularly in this period of the gradual application of the EU HTA Regulation.”
The HAG plays an important role in supporting strong partnerships, promoting effective and efficient solutions for a European HTA collaboration, and enhancing the impact of HTA on decision-making and on European healthcare systems. This is achieved by:
- facilitating information and experience sharing between organisations;
- supporting cooperation and addressing key strategic issues for the European HTA network;
- and by advising policy makers and relevant EU and national institutions on matters regarding HTA, particularly cooperation in HTA.
- Support the joint work under the Regulation (EU) 2021/2282 on health technology assessment (HTAR)
